Article Details

Pieris Pharmaceuticals Inc Files Patent for Fusion Polypeptide Binding CD137 and GPC3 for ...

Retrieved on: 2024-06-11 18:17:01

Tags for this article:

Click the tags to see associated articles and topics

Pieris Pharmaceuticals Inc Files Patent for Fusion Polypeptide Binding CD137 and GPC3 for .... View article details on hiswai:

Excerpt

Discover the groundbreaking fusion polypeptide patent by Pieris Pharmaceuticals targeting CD137 and GPC3 for anti-cancer therapies.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up